A Review of the Effects of Transcranial Direct Current Stimulation for the Treatment of Hallucinations in Patients With Schizophrenia

The Journal of ECT
Marine MondinoJérôme Brunelin

Abstract

Some 25% to 30% of patients with schizophrenia report auditory verbal hallucinations (AVHs) that fail to respond adequately to antipsychotic treatments. In such cases, transcranial direct current stimulation (tDCS) has been proposed as a therapeutic option. Here, we aim to provide an exhaustive review of the literature examining the clinical effects of tDCS on AVH in patients with schizophrenia. A systematic search in the PubMed and Web of Science databases yielded 14 results, 7 randomized controlled trials (RCTs) and 7 open-label studies. Among them, 4 RCTs and 7 open-label studies reported a significant reduction of AVH after repeated sessions of tDCS, whereas 3 RCTs did not show any advantage of active tDCS over sham tDCS. Altogether, current studies showed an overall decrease of approximately 26% of AVH after active tDCS and 11% after sham tDCS. One suitable approach to decreasing AVH was to deliver twice-daily sessions of tDCS over 5 consecutive days (10 sessions at 20 minutes each, 2 mA) with the anode over the left dorsolateral prefrontal cortex and the cathode over the left temporoparietal junction. Demographic and clinical parameters such as young age, nonsmoking status, and higher frequencies of AVH occurrence seemed ...Continue Reading

References

Mar 24, 2006·The European Journal of Neuroscience·Michael A NitscheWalter Paulus
May 16, 2008·Epidemiologic Reviews·John McGrathJoy Welham
Mar 31, 2009·Schizophrenia Research·Rajiv TandonMatcheri S Keshavan
Jan 29, 2010·Journal of Neurophysiology·Katia Monte-SilvaMichael A Nitsche
Oct 19, 2010·The American Journal of Psychiatry·Renaud JardriPierre Thomas
Mar 1, 2012·Schizophrenia Bulletin·Iris E C SommerMark van der Gaag
May 15, 2012·The American Journal of Psychiatry·Jerome BrunelinEmmanuel Poulet
Jan 11, 2013·The Journal of ECT·Pedro ShiozawaAndre Russowsky Brunoni
Feb 26, 2013·Brain Stimulation·Gopalkumar RakeshGanesan Venkatasubramanian
Feb 26, 2013·Schizophrenia Research·Pedro ShiozawaAndre Russowsky Brunoni
Jun 27, 2013·Schizophrenia Research·Rajiv TandonWilliam Carpenter
Oct 30, 2013·Neuromodulation : Journal of the International Neuromodulation Society·Gökben Hızlı SayarGül Eryılmaz
Dec 10, 2013·Biological Psychiatry·Christina W SlotemaIris E C Sommer
Feb 11, 2014·Brain Stimulation·Hema NawaniGanesan Venkatasubramanian
Apr 29, 2014·Schizophrenia Research·Anushree BoseGanesan Venkatasubramanian
May 6, 2014·Journal of Psychiatric Research·A MillierN Cadi-Soussi
May 23, 2014·Schizophrenia Bulletin·Judith M FordBruce N Cuthbert
Jun 18, 2014·Frontiers in Aging Neuroscience·Hakuei FujiyamaJeffery J Summers
Jun 14, 2015·Asian Journal of Psychiatry·Venkataram ShivakumarGanesan Venkatasubramanian
Dec 15, 2015·Acta Psychiatrica Scandinavica·R UpthegroveS J Wood
Jan 19, 2016·Lancet·Michael J OwenPreben B Mortensen
Feb 13, 2016·European Psychiatry : the Journal of the Association of European Psychiatrists·F FröhlichL F Jarskog
Mar 25, 2016·Indian Journal of Psychological Medicine·Venkataram ShivakumarGanesan Venkatasubramanian
Jul 31, 2016·Neuroscience and Biobehavioral Reviews·Leor ZmigrodJon S Simons

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here